Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.70 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.70 |
| ▸ | CDC25B | P30305 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GLRA3 | O75311 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13835863 | 1.00 | PTPN1 (0.70) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL1723909 | 0.96 | ALOX15 (0.75) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL1713838 | 0.96 | ALOX15 (0.75) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL1713835 | 0.96 | ALOX15 (0.75) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL1713839 | 0.96 | ALOX15 (0.75) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL23298141 | 0.96 | ALOX15 (0.75) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL2595100 | 0.94 | ALOX15 (0.71) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL13835667 | 0.94 | ALOX15 (0.71) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL13836453 | 0.89 | PTPN1 (0.55) | PTPN1PTPN2CDC25BALOX15PTGS1 | |
| SCHEMBL2592605 | 0.89 | PTPN1 (0.55) | PTPN1PTPN2CDC25BALOX15PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354618-A1 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | EDISON PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20130109759-A1 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | EDISON PHARMACEUTICALS, INC. | 2013-05-02 | — | — | US | disclosed |
| EP-2563352-A1 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | Edison Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120295985-A1 | METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL | EDISON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012068552-A1 | METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL | EDISON PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011137126-A1 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109759-A1 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | MT-ND1, NDUFA7, NDUFA11 | PTPN1 4106/4885PTPN2 4373/4885CDC25B 1291/4885 |
| US-20170354618-A1 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | MT-ND1, NDUFA7, NDUFA11 | PTPN1 4106/4885PTPN2 4373/4885CDC25B 1291/4885 |
| US-20120295985-A1 | METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL | SLC2A1, GPR119, SLC2A3 | PTPN1 1219/4885PTPN2 1108/4885CDC25B 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.